Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The most common complication of chronic lymphocytic leukaemia (CLL) is infection, which occurs mainly in advanced stages of disease or in those patients with hypogammaglobulinaemia. Intravenous immune globulin (IVIG) has been shown to be a useful prophylactic therapy against infections in such patients. A randomized, double-blind study on 36 patients receiving either 500 mg/kg or 250 mg/kg IVIG every 4 weeks was undertaken to determine the dose regimen required. There was no significant difference in the two treatment groups and we found that CLL patients were equally protected with low-dose IVIG.


Conference paper

Publication Date



97 Suppl 1


17 - 20


Universitätsklinik Mainz, Abt. Hämatologie, Germany.


Humans, Bacterial Infections, Opportunistic Infections, Agammaglobulinemia, Immunoglobulin G, Immunoglobulins, Intravenous, Neoplasm Staging, Double-Blind Method, Female, Male, Leukemia, Lymphocytic, Chronic, B-Cell